Farmas USA

SNSS

http://www.biomedreports.com/2012060796532/sunesis-has-been-enjoying-a-rally-thus-far-in-2012.html

Nos tenemos que esperar al Tercer trimestre de 2012 para ver si le aprueban el medicamento.

cosas del traductor de google,no lo se pincha en el link

SNSS

Exelixis reported additional positive data from a Phase III pivotal trial evaluating cabozantinib in the treatment of progressive, unresectable, and locally advanced or metastatic medullary thyroid cancer (MTC). The firm completed its cabozantinib NDA submission to FDA for the MTC indication at the end of May.

Carried out under Special Protocol Assessment with FDA, the placebo-controlled Exam study involved 330 patients. The study met its primary endpoint in terms of increasing median progression free survival (PFS) from 4 months (for placebo-treated patients) to 11.2 months for patients in the capozantinib arm. Cabozantinib therapy was associated with an estimated PFS at one year of 47.3%, compared with 7.2% for placebo. The overall response rate was 28% for cabozantinib-treated patients, and 0% among placebo-treated patients. Data for overall survival isn’t yet mature, Exelixis reports.

Cabozantinib is a targeted therapy that inhibits MET, VEGFR2, and RET, and has demonstrated tumoricidal, antimetastatic, and antiangiogenic effects. “Beyond MTC, we are also excited about the encouraging interim cabozantinib data that has been generated in a variety of other tumor indications, including hepatocellular carcinoma, renal cell carcinoma, and castration-resistant prostate cancer,” comments Michael M. Morrissee, Ph.D., president and CEO at Exelixis. “In particular, the prostate cancer data formed the basis for advancing cabozantinib into two recently initiated Phase III pivotal trials, Comet-1 and Comet-2." 

EditO

http://www.genengnews.com/gen-news-highlights/phase-iii-study-shows-exelixis-cabozantinib-triples-pfs-in-metastatic-medullary-thyroid-cancer/81246851/#utm_medium=twitter%26utm_medium=social%26utm_campaign=june

ACHN
Más sobre Elizabeth Olek:
S2

http://www.marketwatch.com/story/achillion-announces-resignation-of-chief-medical-officer-2012-06-06

Bueno, mañana suben todas un 180%, y es que mi bebita ya está por aqui. No ha decidido hasta no ver como se ha relajado la prima de riesgo, je je.

Saludos desde un hospital público español donde milagrosamente se sigue investigando, los profesionales estan mas motivados que nunca y las personas son personas y no apuntes contables. Merece la pena luchar por esto y las empresas que defienden este modelo

Enhorabuena papi !

Enhorabuena, que seáis muy muy muy felices.

Enhorabuena a los tres